

10/763,877

=> d his

(FILE 'HOME' ENTERED AT 15:53:49 ON 20 JUN 2006)

FILE 'REGISTRY' ENTERED AT 15:54:03 ON 20 JUN 2006

L1 STRUCTURE UPLOADED

L2 1 S L1

L3 9 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 15:54:45 ON 20 JUN 2006

L4 2 S L3

FILE 'HCAPLUS, HCAOLD, USPATFULL, EPFULL, BIOSIS' ENTERED AT 15:56:01 ON
20 JUN 2006

L5 7852 S ?PHENYL UREA OR ACYL PHENYL UREA?

L6 873 S L5 AND (DIABETES OR BLOOD SUGAR OR BLOOD GLUCOSE OR HYPOGLYC

L7 858 S L6 AND (PHARMACEUTICAL OR TREAT? OR COMPOSITION)

L8 1 S L7 AND ACYLPHENYLUREA


10/763,877

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 15:54:21 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 27 TO ITERATE

100.0% PROCESSED 27 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 229 TO 851

PROJECTED ANSWERS: 1 TO 80


L2 1 SEA SSS SAM L1

=> d scan

L2 1 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN

IN Butanoic acid, 4-[[[4-(2-carboxyethenyl)-3-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]phenyl]amino]-4-oxo- (9CI)

MF C21 H16 Cl F2 N3 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

10/763,877


```
=> s ll full
FULL SEARCH INITIATED 15:54:29 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      397 TO ITERATE
```

```
100.0% PROCESSED      397 ITERATIONS                      9 ANSWERS
SEARCH TIME: 00.00.01
```

L3 9 SEA SSS FUL L1

=> d scan


L3 9 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Butanoic acid, 4-[[[4-(2-carboxyethenyl)-3-[[[(2-chloro-4,5-
difluorobenzoyl)amino]carbonyl]amino]phenyl]amino]-4-oxo- (9CI)
MF C21 H16 Cl F2 N3 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1) :5


```
L3 9 ANSWERS  REGISTRY  COPYRIGHT 2006 ACS on STN
IN  Benzamide, N-[[[5-(acetylamino)-2-chlorophenyl]amino]carbonyl]-2,4-
MF  dichloro- (9CI)
    C16 H12 Cl3 N3 O3
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


```
L3 9 ANSWERS  REGISTRY  COPYRIGHT 2006 ACS on STN
IN  Benzamide, N-[[[5-(acetylamino)-2-chlorophenyl]amino]carbonyl]-2-chloro-
    4,5-difluoro- (9CI)
MF  C16 H11 Cl2 F2 N3 O3
```

10/763,877




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 9 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2-Propenoic acid, 3-[4-(acetamido)-2-[[[(2-chloro-4,5-
difluorobenzoyl)amino]carbonyl]amino]phenyl]- (9CI)
MF C19 H14 Cl F2 N3 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 9 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2-Propenoic acid, 3-[4-[(carboxyacetyl)amino]-2-[[[(2-chloro-4,5-
difluorobenzoyl)amino]carbonyl]amino]phenyl]- (9CI)
MF C20 H14 Cl F2 N3 O7



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 9 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN 2-Propenoic acid, 3-[4-(acetamido)-2-[[[(2-chloro-4,5-
difluorobenzoyl)amino]carbonyl]amino]phenyl]-, methyl ester (9CI)
MF C20 H16 Cl F2 N3 O5

10/763,877



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file hcaplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
166.94	167.15

FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 15:54:45 ON 20 JUN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Jun 2006 VOL 144 ISS 26
FILE LAST UPDATED: 19 Jun 2006 (20060619/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 2 L3

=> d 1-2 ibib abs hitstr


L4 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:980048 HCAPLUS
DOCUMENT NUMBER: 143:359432
TITLE: Acyl Ureas as Human Liver Glycogen Phosphorylase Inhibitors for the Treatment of Type 2 Diabetes
AUTHOR(S): Klabunde, Thomas; Wendt, K. Ulrich; Kadereit, Dieter;

Brachvogel, Volker; Burger, Hans-Joerg; Herling, Andreas W.; Oikonomakos, Nikos G.; Kosmopoulou, Magda N.; Schmoll, Dieter; Sarubbi, Edoardo; Von Roedern, Erich; Schoenafinger, Karl; Defossa, Elisabeth
 CORPORATE SOURCE: Scientific and Medical Affairs, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, D-65926, Germany
 SOURCE: Journal of Medicinal Chemistry (2005), 48(20), 6178-6193
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:359432

AB Using a focused screening approach, acyl ureas have been discovered as a new class of inhibitors of human liver glycogen phosphorylase (hlGPa). The x-ray structure of screening hit 1 (IC₅₀ = 2 µM) in a complex with rabbit muscle glycogen phosphorylase b reveals that 1 binds at the AMP site, the main allosteric effector site of the dimeric enzyme. A first cycle of chemical optimization supported by x-ray structural data yielded derivative 21, which inhibited hlGPa with an IC₅₀ of 23±1 nM, but showed only moderate cellular activity in isolated rat hepatocytes (IC₅₀ = 6.2 µM). Further optimization was guided by (i) a 3D pharmacophore model that was derived from a training set of 24 compds. and revealed the key chemical features for the biol. activity and (ii) the 1.9 Å crystal structure of 21 in complex with hlGPa. A second set of compds. was synthesized and led to 42 with improved cellular activity (hlGPa IC₅₀ = 53±1 nM; hepatocyte IC₅₀ = 380 nM). Administration of 42 to anesthetized Wistar rats caused a significant reduction of the glucagon-induced hyperglycemic peak. These findings are consistent with the inhibition of hepatic glycogenolysis and support the use of acyl ureas for the treatment of type 2 diabetes.


IT 866329-41-1P 866329-42-2P 866329-44-4P 866329-45-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (acyl ureas as human liver glycogen phosphorylase inhibitors for treatment of type 2 diabetes)

RN 866329-41-1 HCAPLUS
 CN Benzamide, N-[[[5-(acetylamino)-2-chlorophenyl]amino]carbonyl]-2,4-dichloro- (9CI) (CA INDEX NAME)




RN 866329-42-2 HCAPLUS
 CN Benzamide, N-[[[5-(acetylamino)-2-methoxyphenyl]amino]carbonyl]-2,4-dichloro- (9CI) (CA INDEX NAME)

10/763,877




RN 866329-44-4 HCAPLUS

CN Benzamide, N-[[[5-(acetylamino)-2-chlorophenyl]amino]carbonyl]-2-chloro-4,5-difluoro- (9CI) (CA INDEX NAME)



RN 866329-45-5 HCAPLUS

CN Benzamide, N-[[[5-(acetylamino)-2-methoxyphenyl]amino]carbonyl]-2-chloro-4,5-difluoro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:991475 HCAPLUS

DOCUMENT NUMBER: 140:41915

TITLE: Preparation of N-benzoylureidophenylacrylic acids as antidiabetic agents

INVENTOR(S): Schoenafinger, Karl; Defossa, Elisabeth; Kadereit, Dieter; Von Roedern, Erich; Klabunde, Thomas; Burger, Hans-Joerg; Herling, Andreas; Wendt, Karl-Ulrich

PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany

SOURCE: PCT Int. Appl., 42 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003104188	A1	20031218	WO 2003-EP5355	20030522
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


DE 10225635	C1	20031224	DE 2002-10225635	20020607
CA 2488760	AA	20031218	CA 2003-2488760	20030522
AU 2003238373	A1	20031222	AU 2003-238373	20030522
BR 2003011646	A	20050315	BR 2003-11646	20030522
EP 1513800	A1	20050316	EP 2003-732438	20030522

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK


CN 1659137	A	20050824	CN 2003-813173	20030522
JP 2005529164	T2	20050929	JP 2004-511258	20030522
US 2004102518	A1	20040527	US 2003-456570	20030606
US 7049341	B2	20060523		
NO 2005000087	A	20050106	NO 2005-87	20050106

PRIORITY APPLN. INFO.: DE 2002-10225635 A 20020607
US 2002-411982P P 20020919
WO 2003-EP5355 W 20030522

OTHER SOURCE(S): MARPAT 140:41915
GI



I



II

AB Title compds. I [R7, R8, R9, R10 = H, halo, OH, etc.; R1, R2 = H, (un)substituted alkyl, e.g., OH, O-alkyl, NH2, etc.; R3, R4, R5, R6 = H, halo, NO2, etc.; R11 = OR12, NR18R19; R12 = H, alkyl, alkenyl, etc.; R18, R19 = H, alkyl, alkenyl, etc.;] and their pharmaceutically acceptable salts were prepared For example, condensation of 2-chloro-4,5-difluorobenzoylisocyanate, e.g., prepared from 2-chloro-4,5-difluorobenzamide and oxalyl chloride, and 3-(2-aminophenyl)acrylic acid afforded N-benzoylureidocinnamate II in 76% yield. In glycogen phosphorylase-A inhibition assays, 14-examples of compds. I at 10 μ M exhibited 83->100% inhibition (sic),. Compds. I are claimed useful as as antidiabetic agents.

IT 634616-74-3P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

10/763,877

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(target compound; preparation of N-benzoylureidophenylacrylic acids as antidiabetic agents)

RN 634616-74-3 HCAPLUS

CN 2-Propenoic acid, 3-[4-(acetylamino)-2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]phenyl]-, methyl ester (9CI) (CA INDEX NAME)




IT 634616-62-9P 634616-63-0P 634616-64-1P
634616-65-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of N-benzoylureidophenylacrylic acids as antidiabetic agents)


RN 634616-62-9 HCAPLUS

CN 2-Propenoic acid, 3-[4-(acetylamino)-2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 634616-63-0 HCAPLUS


CN 2-Propenoic acid, 3-[4-[(carboxycarbonyl)amino]-2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 634616-64-1 HCAPLUS


10/763,877

CN 2-Propenoic acid, 3-[4-[(carboxyacetyl)amino]-2-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 634616-65-2 HCAPLUS

CN Butanoic acid, 4-[[4-(2-carboxyethenyl)-3-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]phenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT